PHARMAC Performance 2019/20 – Quarter 3
Output Class 1: Making decisions about medicines and medical devices
Measure: Savings are made to meet the cost of future volume growth and allow for new investments.
Status: On track. In the 2019/20 year to 31 March 2020, PHARMAC listed 13 new medicines and expanded access to 32 more, at a gross cost of $31.5 million, from within the available budget.
Measure: The total value and number of hospital medical devices under national contract increases.
Status: On track. Expenditure under contract increased by almost $2 million in quarter 3. We listed around 2,000 new medical devices this quarter. The total number of medical devices is now 116,000.
Output Class 2: Influencing medicines access and use
Measure: DHB hospital engagement with PHARMAC compared with previous year.
Status: On track. 25 DHBs and their agents made submissions through our consultation on managing fairer access to hospital medical devices.
Measure: Primary care organisations/representative bodies value their relationships with PHARMAC.
Status: On track. PHARMAC and the Health Quality Safety Commission are partnering to support a behavioural insights trial to support appropriate antimicrobial prescribing.
Measure: Improvements to transparency of PHARMAC’s decision making processes.
Status: On track. We have streamlined our processes for correspondence and general inquires, with a target response time of five days. We have also improved our process for responding to OIAs.
Another 17 inactive funding applications were declined this quarter. This work will assist in making it clear what applications PHARMAC is considering for funding and which are not being actively considered.
Measure: Survey of attendants at a PHARMAC seminar show a positive professional change in optimal use behaviour as a result of attendance.
Status: Not achieved. Surveys of attendees are sent two to three months after the completion of the seminar. Eight seminars held in the 2019/20 financial year have been surveyed with 78% of respondents indicating they have made a change in practice as a result of attending a seminar.
Measure: Medicines use community health programmes are delivered to a range of health and community workers.
Status: On track. Three Whānau Ora Collective events were completed in the North Island this quarter.
Measure: Engagement by primary health care professionals with responsible use materials developed by PHARMAC service providers.
Status: On track. PHARMAC is engaging with service providers to embed reporting requirements for current responsible use contracts to measure uptake of responsible use materials by primary care providers.
Measure: A framework is developed for measuring and monitoring equitable access to medicines.
Status: On track. Work has commenced on the Medicine Access Monitoring and Outcomes Framework, including establishing baseline data for the indicators in the Framework.
Measure: A baseline target is developed for rate of medicines dispensed to Māori compared to non-Māori.
Status: On track. PHARMAC have been undertaking work to refine the methodology that underpins this measure. The target will be set once a baseline for existing indicators are established.
Measure: Low medicine stock situations are identified and actively managed so that there are sustained or irreversible impacts on patient health.
Status: On track. Potential low stock issues have been managed and alternative supply options secured where required. There have been no out of stock situations that have had a sustained or irreversible impact on the health of patients this quarter.
Output Class 3: Providing policy advice and support
Measure: PHARMAC staff participate in and contribute to wider sector forums.
Status: On track. PHARMAC regularly engages with the Ministry of Health on a number of policy issues, including early access to new cancer medicines; the Cancer Action Plan; abortion law reform; and medicinal cannabis.
Measure: All rebates are collected and distributed to DHBs in accordance with PHARMAC policy.
Status: On track. All fund use is in accordance with PHARMAC policy.
Measure: PHARMAC is involved in, or contributes to, research which supports PHARMAC’s core functions and strategic priorities.
Status: On track. PHARMAC runs an annual request for proposals for research initiatives. PHARMAC, in partnership with the Health Research Council, approved two research applications which will contribute to supporting PHARMAC’s core functions and strategic priorities.
Last updated: 15 May 2020